Open AccessP21: SUBSEQUENT ANTI‐MYELOMA THERAPY AFTER IDECABTAGENE VICLEUCEL (IDE‐CEL, BB2121) TREATMENT IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA FROM THE KARMMA STUDY
Author(s) -
RodríguezOtero P,
SanMiguel J,
Anderson LD,
Lonial S,
TruppelHartmann A,
Sanford J,
Rowe E,
Campbell TB,
Munshi N
Publication year - 2022
Publication title -
hemasphere
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 11
ISSN - 2572-9241
DOI - 10.1097/01.hs9.0000829656.69351.86
Subject(s) - medicine , cyclophosphamide , multiple myeloma , regimen , refractory (planetary science) , fludarabine , gastroenterology , oncology , chemotherapy , physics , astrobiology